ScreenerHero
IDIAIdorsia Ltd
SWX · CH · Healthcare · Biotechnology · idorsia.com
5.550CHF-0.89%Mkt Cap: 1.68B $P/E: —

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap1.68B $
Enterprise Value3.09B $
Revenue (TTM)227.93M $
Gross Profit227.89M $
Net Income (TTM)-127.48M $
Revenue/Share0.9336 USD
Last Price5.550 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees424
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0363463438
Valuation
P/E (Trailing)—
P/E (Forward)97.98
PEG—
EV/EBITDA-19.43
EV/Revenue13.54
P/S7.19
P/B-1.19
EPS (TTM)-1.33
EPS (Forward)0.06
52W Range
2.41561% of range7.560
52W High7.560 CHF
52W Low2.415 CHF
Profitability
Gross Margin90.52%
Oper. Margin-68.86%
EBITDA Margin-69.66%
Profit Margin-50.64%
ROE9.82%
ROA-23.98%
Growth
Revenue Growth-26.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-174.88M $
CapEx (TTM)15.77M $
FCF Margin-17.62%
FCF Yield-2.39%
Net Debt1.40B $
Net Debt/EBITDA-8.85
Balance Sheet
Debt/Equity-1.11
Current Ratio0.58
Quick Ratio0.36
Book Value/Sh-4.5390 CHF
Cash/Share0.3370 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2017
Pay DateOct 13, 2020
Analyst Consensus
Rating—
Target (Mean)5.000 CHF
Upside (mean)-9.9%
Target Range4.500 CHF – 5.500 CHF
CHF4.500-9.9% to meanCHF5.500
# Analysts3
Ownership
Shares Out.265.12M
Float148.87M
Insiders30.74%
Institutions27.18%
Technical
SMA 506.048 (-8.2%)
SMA 2004.340 (+27.9%)
Beta1.66
S&P 52W Chg18.16%
Avg Vol (30d)1.36M
Avg Vol (10d)1.51M
Technical Indicators
RSI (14)43.6
MACD-0.0321
MACD Signal0.0497
MACD Hist.-0.0817
BB Upper6.816 CHF
BB Middle6.115 CHF
BB Lower5.414 CHF
BB Width22.92%
ATR (14)0.4231 CHF
Vol Ratio (20d)0.58x